H.C. Wainwright upgraded AnaptysBio (ANAB) to Buy from Neutral with a $38 price target after the company announced week 28 data from the Phase 2 rheumatoid arthritis trial which met its primary endpoint. The firm says that given the data “showcase a positive holistic story” for rosnilimab in rheumatoid arthritis, it is increasingly positive on upcoming ulcerative colitis data. AnaptysBio’s week 28 data compare favorably with competitor datasets, such as JAK inhibitors, contends H.C. Wainwright.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Promising Potential of AnaptysBio’s Rosnilimab: A Buy Rating Backed by Strong Phase 2b Trial Results and Strategic Outlook
- Closing Bell Movers: Guidewire up 11% after Q3 beat, guidance raise
- AnaptysBio Reports Positive Phase 2b Trial Results
- AnaptysBio announces investigational rosnilimab data
- AnaptysBio price target raised to $90 from $54 at Guggenheim